Addressing drug effects on cut point determination for an anti-drug antibody assay.

The effect of trough levels of a monoclonal antibody drug (drugB) on screening cut point (CP) determination for an anti-drug antibody (ADA) assay was scrutinized and the conclusions substantiated by data from a phase 3 cancer clinical study. The ADA assay utilized an acid dissociation step and either 0 or 100 µg/ml drugB was added to the samples prior to obtaining the signals used for CP calculations. Serum samples from three different drug-naive populations were tested (healthy individuals, cancer patients enrolled in the drugB clinical trial and cancer patients whose serum samples were available commercially). For the same disease state samples, both the screening CP and confirmation CP were different when calculated during validation or from study sample analysis. It is reasonable to assume that variability was due to the patient heterogeneity, as they could have been at distinct stages of disease progression, and/or taking different medications, amongst other differences. The patients enrolled in the clinical trial were stratified as per protocol and hence represented a more homogeneous population. Drug effects on CP may be population dependent and also assay dependent.

Validation and life-cycle management of a quantitative ligand-binding assay for the measurement of Nulojix(®), a CTLA-4-Fc fusion protein, in renal and liver transplant patients.

BACKGROUND: Nulojix(®) is a fusion protein composed of the Fc portion of a human IgG1 linked to the extracellular modified domain of CTLA-4. Nulojix differs from another Bristol Myers Squibb product, Orencia(®) by two amino acids and was approved by the FDA on 15 June 2011 for the prophylaxis of organ rejection in adult patients receiving kidney transplant. RESULTS: A sandwich ELISA utilizing two monoclonal antibodies against CTLA-4 was employed for Nulojix quantification and pharmacokinetic analysis. At least 17 analysts have qualified on the assay and contributed to reportable results over the last 7 years. In-study accuracy and precision demonstrate suitable performance: %bias within -4 to 4%, %CV ≤13% and total error within 6-15%. Incurred sample reanalysis was completed in applicable disease-state populations. The assay was automated and validated in additional clinical matrices (ascites and urine) and Nulojix quantification was validated in the presence of clinically relevant co-administered compounds. In 2011, the biotinylation procedure was modified meriting a regression change (quadratic to 4-parameter logistic) and associated partial validation. CONCLUSION: This long-term pharmacokinetic program provides a good example of the dynamic clinical environment and adaptation requirements of ligand-binding assays.

How hair cells hear: the molecular basis of hair-cell mechanotransduction.

PURPOSE OF REVIEW: This review aims to summarize our current knowledge regarding mechanotransduction by hair cells and to highlight unresolved questions. RECENT FINDINGS: Despite over a quarter of a century of electrophysiological data describing hair-cell mechanotransduction, the molecular basis of this process is just now being revealed. Recent work has begun to identify candidate transduction complex molecules, and current work is aimed at confirming these hypotheses and identifying other proteins important for hair-cell function. SUMMARY: Our senses of hearing and balance rely on the exquisite sensitivity of the hair cell and its transduction complex. Understanding the molecular basis for hair-cell mechanotransduction may provide us with the foundation for understanding the causes of, and perhaps the treatments for, auditory and vestibular deficits resulting from hair-cell dysfunction.

In situ binding assay to detect Myosin-1c interactions with hair-cell proteins.

Myosin-1c is an unconventional myosin involved in hair-cell mechanotransduction, a process that underlies our senses of hearing and balance. To study the interaction of myosin-1c with other components of the hair-cell transduction complex, we have developed an in situ binding assay that permits visualization of myosin-1c binding to hair-cell proteins. In this chapter we describe in detail the methods needed for the expression and purification of recombinant myosin-1c fragments and their use in the in situ binding assay.

Stereociliary myosin-1c receptors are sensitive to calcium chelation and absent from cadherin 23 mutant mice.

The identities of some of the constituents of the hair-cell transduction apparatus have been elucidated only recently. The molecular motor myosin-1c (Myo1c) functions in adaptation of the hair-cell response to sustained mechanical stimuli and is therefore an integral part of the transduction complex. Recent data indicate that Myo1c interacts in vitro with two other molecules proposed to be important for transduction: cadherin 23 (Cdh23), a candidate for the stereociliary tip link, and phosphatidylinositol 4,5-bisphosphate (PIP2), which is abundant in the membranes of hair-cell stereocilia. It is not known, however, whether these interactions occur in hair cells. Using an in situ binding assay on saccular hair cells, we demonstrated previously that Myo1c interacts with molecules at stereociliary tips, the site of transduction, through sequences contained within its calmodulin (CaM)-binding neck domain, which can bind up to four CaM molecules. In the current study, we identify the second CaM-binding IQ domain as a region of Myo1c that mediates CaM-sensitive binding to stereociliary tips and to PIP2 immobilized on a solid support. Binding of Myo1c to stereociliary tips of cochlear and vestibular hair cells is disrupted by treatments that break tip links. In addition, Myo1c does not bind to stereocilia from mice whose hair cells lack Cdh23 protein despite the presence of PIP2 in the stereociliary membranes. Collectively, our data suggest that Myo1c and Cdh23 interact at the tips of hair-cell stereocilia and that this interaction is modulated by CaM.